Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung cancer (SCLC). The global DeLLphi-304 trial has been comparing the drug ...

Zuckerman Investment Group injected $521,000 into Amgen by scooping up 1,803 shares during the fourth quarter. A crowd of other investors also hopped aboard the Amgen train, with stakes both large and ...

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and ...

Pharmaceutical company Sandoz has filed a federal lawsuit accusing Amgen of orchestrating an illegal scheme to block biosimilar competition for its blockbuster arthritis drug Enbrel, resulting in ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market ...

Switzerland-based generic drug maker Sandoz said on Monday that it has filed an antitrust lawsuit against Amgen, Inc, (AMGN) ...

Amgen (AMGN) stock in focus as Sandoz files antitrust lawsuit alleging that the company blocked copycats from targeting its ...

Swiss generic and biosimilar medicines firm Sandoz (SIX: SDZ) today announced it has filed an antitrust lawsuit in the USA ...

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block biosimilar competition and allow ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...